Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19

https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.060

Full Text:

Abstract

Background. Severe forms of COVID-19 are associated with the development of a cytokine storm that is characterized by an increased secretion of anti-inflammatory cytokines. Thus, one of the leading strategies of treatment for patients with severe forms of COVID-19 is a decrease in the concentration of anti-inflammatory cytokines and inhibition of their effect on the organism.

Objective: to perform a comparative analysis of clinical and economic constituents of the application of an IL-6 inhibitor tocilizumab and systemic glucocorticosteroid dexamethasone for the therapy of severe conditions in patients with COVID-19 based on the published data review.

Material and methods. The authors analyzed the data obtained from PubMed/MEDLINE databases on the study dedicated to the application of tocilizumab and dexamethasone for the therapy of severe conditions in patients with COVID-19. A statistical evaluation of the influence of these drugs on the 28-day survival rate of patients with a severe form of COVID-19 was performed. The statistical tools included methods of the attribute-based statistic (attribute-based efficiency, relative efficiency (RE), populational attributive efficiency (PAE)). For the visualization of the clinical efficiency of the compared drugs, the authors applied beta-distribution. Markov’s model was used for modeling of the mortality rate. The modeling included the study of a hypothetical cohort of patients (1,000 patients with COVID-19). Besides, the authors evaluated the economic constitutive of the therapy with tocilizumab and dexamethasone. The cost-effectiveness analysis was performed.

Results. The indication of dexamethasone statistically significantly increases the survival rate by 3.1% and tocilizumab – by 22.5%. RE was 1.04 (95% CI 0.040–2.042) for dexamethasone and 1.66 (95% CI 0.400–2.917) for tocilizumab. The lower border of 95% CI for both drugs was within the range of values <1, which was statistically significant. PAE for dexamethasone was 1.0% (95% CI –0.6–2.6), for tocilizumab – 16.5% (95% CI –0.7–33.7). Lower borders of 95% CI for both drugs ranged within negative values, which was not statistically significant. NNT (dexamethasone) was 32; NNT (tocilizumab) was 4. Markov’s modeling showed that the mortality rate among patients who received these drugs was 36 out of 1000 patients with COVID-19 for dexamethasone (initially distributed by the degree of severity according to the official statistical data) and 30 out of 1000 patients for tocilizumab, respectively. The cost of the treatment course with dexamethasone was 107.45 rub., tocilizumab – 78,827.20 rub. Clinical efficiency by the rate of cured patients obtained as a result of Markov’s modeling among patients with severe forms of COVID-19 for both drugs was comparable (0.964 for dexamethasone and 0.970 for tocilizumab) with slightly higher values for tocilizumab.

Conclusion. Despite relatively comparable clinical efficiency of dexamethasone and tocilizumab and a significantly higher cost the later, it is not impossible to replace tocilizumab with dexamethasone because of a great number of side effects and potential inter-drug interactions during the treatment of severe forms of COVID-19. In particular, dexamethasone therapy should be performed with caution in patients with diabetes mellitus. Procurement planning should be made taking account the reserves of tocilizumab for the stabilization of patients with cytokine storm when dexamethasone application is not safe.

About the Authors

O. V. Zhukova
Privolzhskiy Research Medical University
Russian Federation

Olga V. Zhukova – PhD (Pharm.), Head of the Department for Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmacy. RSCI SPIN-code: 4167-1496

10/1Minina i Pozharskogo pl., Nizhniy Novgorod 603950



A. L. Khokhlov
Yaroslavl State Medical University
Russian Federation

Aleksander L. Khokhlov – Dr. Med. Sc., Corresponding Member of the Russian Academy of Sciences, Professor of the Department for the Clinical Pharmacology. RSCI SPIN-code: 9389-8926

5 Revolutsionnaya Str., Yaroslavl 150000



References

1. Huang X., Wei F., Hu L., Wen L., Chen K. Epidemiology and clinical characteristics of COVID-19. Arch Iran Med. 2020; 23 (4): 268–71. https://doi.org/10.34172/aim.2020.09.

2. Zhai P., Ding Y., Wu X., et al. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020; 55 (5): 105955. https://doi.org/10.1016/j.ijantimicag.2020.105955.

3. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19). Outbreak in China: summary of a report of cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323 (13): 1239–42. https://doi.org/10.1001/jama.2020.2648.

4. Yang X., Yu Y., Xu J., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. Lancet Respir Med. 2020; 8 (5): 475–81. https://doi.org/10.1016/S2213-2600(20)30079-5.

5. Makatsariya A.D., Grigoreva K.N., Mingalimov M.A., et al. Coronavirus disease (COVID-19) and disseminated intravascular coagulation syndrome. Obstetrics, Gynecology and Reproduction. 2020; 14 (2): 123–31 (in Russ.). https://doi.org/10.17749/2313-7347.132.

6. Khizroeva J.H., Makatsariya A.D., Bitsadze V.O., et al. Laboratory monitoring of COVID-19 patients and importance of coagulopathy markers. Obstetrics, Gynecology and Reproduction. 2020; 14 (2): 13247 (in Russ.). https://doi.org/10.17749/2313-7347.141.

7. Ye Q., Wang B., Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020; 80 (6): 607–13. https://doi.org/10.1016/j.jinf.2020.03.037.

8. Cellina M., Orsi M., Bombaci F., et al. Favorable changes of CT findings in a patient with COVID-19 nia after treatment with tocilizumab. Diagn Interv Imaging. 2020; 101 (5): 323–4. https://doi.org/10.1016/j.diii.2020.03.010.

9. Xu X., Han M., Li T., et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020; 117 (20): 10970–5. https://doi.org/10.1073/pnas.2005615117.

10. Radbel J., Narayanan N., Bhatt P.J. Use of tocilizumab for COVID-19-induced cytokine release syndrome: a cautionary case report. Chest. 2020; 158 (1): e15–9. https://doi.org/10.1016/j.chest.2020.04.024.

11. Luo P., Liu Y., Qiu L., et al. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020; 92 (7): 814–8. https://doi.org/10.1002/jmv.25801.

12. Biggioggero M., Crotti C., Becciolini A., Favalli E.G. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther. 2018; 13: 57–70. https://doi.org/10.2147/DDDT.S150580.

13. Tanaka T., Narazaki M., Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016; 8 (8): 959–70. https://doi.org/10.2217/imt-2016-0020.

14. Horby P., Shen Lim W., et al. Effect of Dexamethasone in hospitalized patients with COVID-19: preliminary report. https://doi.org/10.1101/2020.06.22.20137273.

15. Barnes P.J. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 2006; 148 (3): 245–54. https://doi.org/10.1038/sj.bjp.0706736.

16. Kumar K., Hinks T. S., Singanayagam A. Treatment of COVID-19exacerbated asthma: should systemic corticosteroids be used? Ame J Physiol Lung Cell Mol Physiol. 2020; 318 (6): L1244–7. https://doi.org/10.1152/ajplung.00144.2020.

17. Hui D. S., Lee N., Chan P.K. Adjunctive therapies and immunomodulatory agents in the management of severe influenza. Antiviral Res. 2013; 98 (3): 410–46. https://doi.org/10.1016/j.antiviral.2013.03.019.

18. De Wit E., Van Doremalen N., Falzarano D., Munster V.J. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14 (8): 523–34. https://doi.org/10.1038/nrmicro.2016.81.

19. Auyeung T.W., Lee J.S., Lai W.K., et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect. 2005; 51 (2): 98–102. https://doi.org/10.1016/j.jinf.2004.09.008.

20. Ho J.C., Ooi G.C., Mok T.Y., et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med. 2003; 168 (12): 1449–56. https://doi.org/10.1164/rccm.200306-766OC.

21. Yam L.Y., Lau A.C., Lai F.Y., et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect. 2007; 54(1): 28–39. https://doi.org/10.1016/j.jinf.2006.01.005.

22. Сhen R.C, Tang X.P., Tan S.Y., et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006; 129 (6): 1441–52. https://doi.org/10.1378/chest.129.6.1441.

23. Corticosteroids for COVID-19. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1 (accessed 12.03.2021).

24. Somers E.C., Eschenauer G.A., Troost J. P., et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020; ciaa954. https://doi.org/10.1093/cid/ciaa954.

25. Annane D., Bellissant E., Bollaert P.E., et al. Corticosteroids for treating sepsis. Cochrane Database Syst Rev. 2015; 2015 (12): CD002243. https://doi.org/10.1002/14651858.CD002243.pub3.


For citation:


Zhukova O.V., Khokhlov A.L. Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2021;14(1):16-27. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.060

Views: 174


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)